Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Extension Study of NBI-827104 in Pediatric EECSWS
2021-006788-11Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NBI-827104 in Continuous spike and wave during slow-wave sleep (CSWS), sponsored by Neurocrine Biosciences. Primary endpoint: Serious treatment-emergent adverse events. Started Feb 2022; status: completed.
02
Drugs
NBI-827104
03
Conditions
Continuous spike and wave during slow-wave sleep (CSWS)
Beyond the preview
Go deeper on 2021-006788-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006788-11.